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Abstract
Stroke is the leading cause of disability and a primary cause of mortality, resulting in an
estimated $33 billion dollars spent on healthcare, rehabilitation and lost productivity in the
United States each year. The most prevalent cause of stroke incidents are acute ischemic events,
manifested as blood clots in the vasculature supplying the brain. Current gold standard
treatments have improved since 2006 with the introduction of mechanical stent retrievers;
however, several issues with the current treatments to acute ischemic stroke remain.
Thrombolysis of the clot with a tissue plasminogen activator may lead to weakening the vessel
wall and consequently, hemorrhaging. Mechanical thrombectomy may result in clot
fragmentation causing embolization downstream in a subsequent vessel. The proposed
methodologies for emboli analog (EA) formation and in-vitro model for AIS simulation offer
platforms for continued development of retrieval mechanism prototypes. EAs were developed in
static and dynamic environments to compare composition and mechanical properties with
cerebral thromboemboli mechanical and physiological properties. EAs formed at 50 RPM with a
vertical rotator were found to be most similar in material stiffness to thromboemboli extracted
from carotid endarterectomy (CEA) procedures (p=0.972). These EAs were also fibrin-rich,
which clinical studies have found that fibrin-rich thromboemboli are linked to lower
recanalization rates. Although the static EAs were not significantly different in material stiffness
from CEA thromboemboli, they are homogenously composed of RBCs. An in-vitro model was
created to simulate AIS physiological parameters including flow rate, temperature and vessel
dimensions for prototype testing as well. A model of the vasculature was created using additive
manufacturing and silicone to mimic cerebral vasculature including the middle cerebral artery,
internal carotid artery and basilar artery where the majority of strokes occur.
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Introduction
Clinical Relevance
Approximately 800,000 people experience a new or recurrent stroke annually translating to
a stroke occurring every 40 seconds and a stroke-related death every 4 minutes (Mozaffarian et
al., 2016). Acute ischemic stroke (AIS) accounts for nearly 90% of strokes (American Heart
Association, 2016) and is typically caused by an embolus or thrombus occluding the middle
cerebral artery (MCA), internal carotid artery (ICA) or the basilar artery (BA) (Schuhmann,
Gunreben, Kleinschnitz, & Kraft, 2016). Arkansas, Mississippi, Louisiana, Tennessee as well as
several other southeastern states lie in the “stroke belt” of the nation. Continuing and advancing
stroke research and awareness is of particular importance in the “stroke belt,” where the average
stroke mortality is 20% higher than the rest of the United States (Mozaffarian et al., 2016).
Current gold standard treatment of stroke include intravenous thrombolysis and mechanical
thrombectomy (American Heart Association, 2015). While intravenous thrombolysis intends to
dissolve the clot, mechanical devices aim to physically extract the entire clot. Each approach has
provided significant improvements in stroke treatment, yet several issues remain.
Recombinant tissue plasminogen activator (tPA) is the only approved FDA approved drug
to treat AIS (American Heart Association, 2015; Paramasivam, 2015). Blood thinners such as
tPA may weaken the blood vessel wall, and consequently increase the risk of hemorrhage. The
drug must be administered intravenously within 4.5 hours of the stroke onset (Paramasivam,
2015). Additionally, tPA is usually ineffective in completely dissolving a clot causing large
vessel occlusion; therefore, mechanical thrombectomy must be employed to achieve
recanalization (American Heart Association, 2015). Related to intravenous thrombolysis,
sonothrombolysis is another method of recanalization in clinical trials. Issues with this method
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include successful recanalization being achieved in less than half of patients treated, increased
risk of hemorrhage, and resistance to lysis by platelet rich clots (Tomkins et al., 2015).
Mechanical devices used for endovascular thrombectomy in stroke patients have continued
to improve since the introduction of the Merci® coil retrieval device (Stryker) was first approved
in 2004 (Paramasivam, 2015). Other FDA approved devices include the TREVO® XP Provue
retriever (Stryker), Penumbra© aspiration retrieval device (Penumbra Inc.) and Solitaire™
revascularization device (Covidien). The main issues with mechanical thrombectomy include
clot fragmentation resulting in new emboli and lengthy procedures (Kurre et al., 2013). Clot
fragmentation may cause a subsequent stroke further downstream, while longer surgical
procedures relate directly to the increased risk of neurons dying from starvation of oxygen-rich
blood. New emboli have been identified in 2-17% of procedures using thrombectomy or a
combined approach of thrombectomy and tPA (Behme et al., 2014; Gascou et al., 2014; Kurre et
al., 2013; Mokin, Setlur Nagesh, Ionita, Mocco, & Siddiqui, 2016). Emboli traveling to the
anterior cerebral artery (ACA) were identified to impact motor or supplementary motor areas of
approximately 3.8% of stroke patients (Kurre et al., 2013). Recent studies also found stent
perforation (1%), stent dislocation (2%) and stent occlusion (5%) to be additional causes of
concern related to mechanical thrombectomy (Behme et al., 2014; Mokin, Fargen, et al., 2016).
The Cover accessory (Lazarus Effect) was designed to surround a stent retriever and prevent clot
fragmentation as well as embolization, but failed to achieve recanalization in 9% of the trial
cases (Mokin, Setlur Nagesh, et al., 2016).
The development of retrieval mechanisms must be engaged with appropriate emboli
analogs (EAs) for prototype testing. Composition of thromboemboli is instrumental in
understanding how a retrieval mechanism will respond while specifically focusing on red blood
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cells (RBCs) and fibrin. RBC-rich thrombi, those having more than 64% erythrocytic material,
are associated with successful reperfusion, while higher percentages of fibrin/platelet
components are linked to unreperfused groups (Hashimoto et al., 2016). Similarly, Yuki et al.
(2012) achieved recanalization for 100% of RBC-rich clots introduced into extracranial arteries
in swine models versus 37.5% recanalization for fibrin-rich clots.
Clinical studies have reported a large variability of thromboemboli composition with
ranges of 0-96% RBCs, 2-100% fibrin, 3-80%platelets, and 0-31% white blood cells (WBCs)
(Boeckh-Behrens et al., 2016; Cline, Carpenter, & Rai, 2013; S. K. Kim et al., 2015; Liebeskind
et al., 2011; Niesten et al., 2014). These findings confirm that a range of EA compositions must
be tested to hone prototype designs of retrieval mechanisms for cerebral thromboemboli. Current
EA models fail to include both composition analysis and mechanical testing to provide EAs with
physiological and mechanical properties that mimic cerebral thromboemboli properties. Further
examination of these models is located under the section 1.4 Current Emboli Analog Models.
Continued research on cerebral thromboemboli and EA material properties is also
necessary to understand clot etiology. Blood flow is essential to fibrin network formation and
therefore, thromboemboli composition and mechanical stability as well (O. V. Kim et al., 2014;
Weisel & Litvinov, 2017). Once fragmentation of the thrombus occurs, an embolus may cause
artery-artery embolism or cardioembolic stroke, which account for nearly 70% of strokes
reported in literature (Chueh et al., 2011; Hashimoto et al., 2016; S. K. Kim et al., 2015; Marder
et al., 2006; Niesten et al., 2014; Schuhmann et al., 2016; Sporns et al., 2017). Approximately
25% of the reported stroke cases were cryptogenic demonstrating a need to further explore clot
etiology with emboli analogs.
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Prototype testing also requires models that include realistic parameters from stroke patients
such as volumetric blood flow rate, vessel diameter and length, tortuosity, and physiological
temperature. Although animal models must be used prior to clinical trials, vessel dimensions and
directions of blood flow in cerebral vasculature vary between animal models and humans. Invitro simulation ensures that the prototype retrieval mechanism is tested with realistic human
parameters. It also allows for flexibility of testing multiple vessel configurations as well as a high
sample number prior to tests with animal models. An overview of published methodology to
produce vessel phantoms is summarized in the subsequent section 1.3 Vasculature Models.

Thrombus Formation
Thrombus formation occurs when an atherosclerotic plaque ruptures and exposes the
subendothelial matrix to initiate platelet recruitment to the injury site. The enzymatic reactions of
the coagulation cascade results in thrombin activation of the platelets resulting in a platelet
“plug” at the injury site as well as fibrinogen to become fibrin monomers (Fogelson & Neeves,
2015). As the enzymatic reactions continue on the activated platelets, fibrinogen binds to the
activated platelets (Weisel & Litvinov, 2017). Activated factor XIII causes fibrin monomers to
become fibrin polymers, which form the thrombus structure and trap RBCs and WBCs.
Fibrin formation, and therefore thrombus composition, is dependent on the volumetric
blood flow rate. Under increasing wall shear rate, fibrin fibers will begin to align parallel to the
flow direction (Onasoga-Jarvis et al., 2014). The authors also discovered that fibrin fiber
diameter decrease with increasing wall shear rate (Onasoga-Jarvis et al., 2014). In Figure 1,
images of fibrin fiber alignment and diameter impacted by a range of wall shear rates may be
seen. Previous research noted by Weisel & Litvinov (2017) found that fibrin fiber orientation
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affects mechanical properties of the clot. Furthermore, the shear force applied by the blood flow
may impact the probability of clot fragmentation and cause an embolus to travel downstream,
thus risking embolization (Weisel & Litvinov, 2017). These findings provide support for EAs to
be formed under dynamic environments rather than initiating coagulation in a test tube or other
static environment. Composition, namely fibrin formation and orientation, is dependent on flow
conditions and therefore, will determine the material stiffness of the embolus.

Figure 1. Fibrin fiber alignment and fiber diameter influenced by increasing wall shear rate
(Onasoga-Jarvis et al., 2014)

Vasculature Models
Initially, an intracranial stroke model (Model #010S) was purchased through Vascular
Simulations (Stony Brook, NY) for prototype testing of a retrieval mechanism. The vascular
model is shown in Figure 2. For this model, the silicone vasculature is at most several
millimeters in thickness. Additionally, it must be suspended in air to connect with a flow loop.
The complexity and construction of the model discouraged use for preliminary prototype tests of
a retrieval mechanism. Although this model realistically replicated the cerebral vasculature,
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concern of puncturing the thin silicone vessels during prototype testing led to investigating
simplified, alternative models.

Figure 2. Intracranial stroke model purchased from Vascular Simulations
(Stony Brook, NY)

In addition to Vascular Simulations, Shelley Medical Imaging Technologies (London,
Ontario, Canada), Metal Professionals (South Range, WI), United Biologics (Tustin, CA), CIRS
(Norfolk, VA) and Blue Phantom (Sarasota, FL) are companies that also fabricate similar
vascular models used primarily for medical training. Purchasing vascular models from a
company was avoided as they did not offer simplified vasculature and could not be easily
replicated. Published methods on producing vascular models also offered several alternatives for
fabricating a vascular phantom model in the laboratory. This provided the opportunity to
replicate the phantom model and create a range of vessel geometries for prototype testing of a
retrieval mechanism.
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The published methods were, however, difficult to replicate as several required specific
additive manufacturing equipment. For example, Ionita et al. (2014) used the Objet Eden 260V
(Stratasys, Eden Prairie, MN) that can print in multiple materials including VeroClear,
TangoPlus and SUP705, which were used to construct the phantom model. Although the authors
have demonstrated an exceptionally accurate method to replicate patient vasculature, the use of
specialized equipment limits the ability to replicate this specific method. Another published
method required a multi-step process including an acrylonitrile butadiene styrene (ABS) core and
shell mold, which was placed in a sodium hydroxide bath to remove support material and
smoothed with xylene and 2-propanol (Chueh, Wakhloo, & Gounis, 2009). The authors then
describe filling the void between the core and shell with silicone, allowing the silicone mold to
cure and removing the ABS in a xylene bath. Others have used wax lumens covered by silicone
and explored silicone coating methods such as a dip-spin procedure or painting layers on the wax
lumen (Knox, Kerber, Singel, Bailey, & Imbesi, 2005; Seong et al., 2005; Sugiu et al., 2003;
Wetzel et al., 2005). In this study, a new approach was undertaken to form a simple, reproducible
cerebral vasculature model for prototype testing of a retrieval mechanism with EAs.

Current Emboli Analog Models
The primary aim of this work is to replicate cerebral emboli due to embolic strokes
identified as the predominant etiology of AIS. Therefore, in-situ formation of clot analogs was
not investigated with vascular models. Several in-vitro methods to form EAs have been
published, but lack a complete picture including the mechanical properties and composition of
each EA in comparison to cerebral thromboemboli. A recent method published by Kan et al.
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(2010) resects a portion of a statically formed clot for emboli injection in swine models. Through
manual elongation, the EAs stretched three times their original length, which demonstrated the
elasticity and mechanical stability of the experimental thrombi (Kan et al., 2010). Metrics for
composition analysis were qualitative – fibrin and RBCs layers in thrombi versus specific
quantities of fibrin, RBCs and other components. Although Kan et al. (2010) demonstrated a new
method to prepare EAs, the lack of quantitative analysis limits comparison with thromboemboli
retrieved from human stroke patients.
Duffy et al. (2016) provides a method for EAs with calculated ranges of fibrin, WBCs and
RBCs, but lacks information on the material stiffness of each EA. Interestingly, Duffy et al.
(2016) found that implementing dynamic conditions with a modified Chandler loop produced a
higher fibrin content of 80% in whole blood clots versus 10% fibrin content in clots made in
static conditions. Based on human, porcine and bovine blood, Chueh et al. (2011) offer EAs
similar in material stiffness to the thromboemboli extracted from carotid endarterectomy (CEA)
and AIS patients, but found their EAs were homogeneously composed of RBCs. A reproducible
method for creating EAs is necessary for prototype testing of stroke retrieval devices, and
requires that the results consistently mimic the desired material stiffness and composition of
cerebral thromboemboli.

Specific Aims and Hypotheses
(1): Develop emboli analogs that mimic material stiffness of stroke thromboemboli. It
is hypothesized that a dynamic system will effectively mimic the in-vivo environment
appropriate for EA formation and offer an EA with similar mechanical properties to stroke
thromboemboli. Additionally, it is hypothesized that measuring and combining specific
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quantities of plasma, RBCs, platelets and thrombin is unnecessary to mimic mechanical
properties and that whole blood may be used to induce clot formation. First, mechanical
differences between EAs formed in static and dynamic environments must be understood.
Second, the relationship between the material stiffness and the speed of the vertical rotator, and
therefore, the shear stress applied to the clot must be examined as well. Results are compared to
published data on the mechanical properties of human cerebral thromboemboli.

(2): Alter emboli analog physiological properties to be fibrin-rich. It is hypothesized
that a dynamic environment induces fibrin-rich EAs and may be adjusted to produce a range of
EA compositions for prototype testing. Histology of tissue samples for static and dynamic
environments is analyzed for percent composition of fibrin and RBCs as they are the main
components in thromboemboli. Composition analysis for EAs formed in a range of dynamic
environments provides a deeper understanding of the differences in their mechanical properties.

(3): Establish in-vitro model to simulate AIS. The key parameters to establish for this
model include physiological temperature, volumetric flow rates and vessel dimensions. The
proposed method offers a platform to replicate cerebral vasculature tortuosity and inner
diameters of the arteries.
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Methodology
Formation of Emboli Analogs
To create EAs, porcine blood was exclusively used, as it is an excellent candidate due to its
similarities to human blood. Specifically, Chueh et al. (2011) found porcine clots resemble the
mechanical stiffness of human stroke clots. Porcine blood anticoagulated with sodium citrate was
obtained from Lampire Biological Laboratories (Pipersville, PA). Totaling a volume of 3 mL, a
9:1 ratio of whole blood and 2.45% (w/v) calcium chloride was pipetted into polyvinyl tubing,
which was closed with a short silicone piece fitted over the polyvinyl tubing. Polyvinyl tubing
inner diameter and length were 6.35 mm and 22 cm, respectively.
Either dynamic or static environments initiated coagulation. A dynamic environment was
created through a modified Chandler loop technique, which mimics the dynamics of blood flow.
As seen in Figure 3, a custom tubing holder was fabricated to attach to a digital Cole-Parmer
MasterFlex® peristaltic pump (Model 7523-50, Vernon Hills, IL). The tubing was placed
equidistance from the central point of rotation. In the dynamic environment, coagulation also
occurred for one hour, while the RPM of the vertical rotator was adjusted to the following
values: 34 RPM, 50 RPM and 80 RPM. As the blood volume was 3 mL, an estimate of the
volumetric blood flow rate may be calculated for each RPM as follows: 102 mL/min (34 RPM),
150 mL/min (50 RPM) or 240 mL/min (80 RPM). These values were chosen based on flow rates
experienced in the ICA (240mL/min), MCA (121 ± 28 mL/min) and BA (100-200 mL/min)
(Kandel, Schwartz, & Jessell, 2000; Oktar et al., 2006; Stock, Wetzel, Lyrer, & Radü, 2000).
Regarding static conditions, contents of the tubing were briefly mixed and left stationary for one
hour on a rod extended from a support stand to ensure emboli analogs formed parallel to the
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ground. An example of the static environment setup is shown in Figure 4 where five static EAs
were formed simultaneously.

Figure 3. Vertical rotator used for inducing dynamic Figure 4. Five replicates of emboli analogs
formed in static environment.
environment for emboli analog production.

Once EA formation was complete, each EA was removed from the tubing and rinsed with
phosphate-buffered saline (PBS) solution prior to obtaining weight and dimension
measurements. Static EAs were especially difficult to remove and remained attached to the
tubing wall. This required the EAs to be flushed from the tubing with PBS. In certain cases, the
static EA remained on the tubing wall and required the tubing wall to be cut with a utility knife.
Once the tubing was opened, the EA was extracted with tweezers. All clots were aged in PBS for
approximately 24 hours following methods previously established for mechanical testing of EAs
(Chueh et al., 2011). One study used EAs for up to 3 weeks for composition analysis (Duffy et
al., 2016); therefore, material stiffness of emboli analogs was compared for two storage
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conditions. Ten EAs formed sequentially at 150 mL/min were used to compare material stiffness
after 24 hours (n=5) in PBS at room temperature and 1 week (n=5) in PBS at 4 °C.

Emboli Analog Measurements
EAs were measured before and after storage in PBS. Final measurements reported are from
the length and width of stored EAs. Once the EAs had been stored for approximately 24 hours,
the EA was removed from the storage container and blotted with a Kimwipe tissue to remove
excess liquid. The mass of each EA was recorded with a digital scale while the length and width
of the EA was recorded with a standard ruler.

Emboli Analog Dissection
Following EA measurements, dissection of EAs for compression testing was performed
using a dissection microscope and ruler. EAs dissected transversely resulted in small
cylindrically shaped tissue segments with an approximate height of 2 mm. Due to the
heterogeneity of the EAs, at least two sections provided an average material stiffness for each
EA. Prior to compression testing, a caliper was used to measure the diameter and height of each
tissue section.

Biomechanical Compression Testing of Emboli Analogs
For direct comparison with published biomechanical testing results on the material
stiffness of human thromboemboli and previous methods for emboli analog formation, the
compression testing method of Chueh et al. (2011) was closely followed using an Instron 3300
(Instron, Norwood, MA) and load cell of 2 kN. Tissue samples were subjected to a force ramp
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rate of 0.5 N/min. It is to be noted that a submersion compression clamp was not available for
use and compression tests were performed at room temperature. Tissue samples were centrally
placed on the compression disk. Two examples of the tissue segments from static and dynamic
EAs are shown in Figure 5. Bluehill® Universal Software (Instron, Norwood, MA) collected
compression testing data at a sampling rate of 10 Hz.

A

B

Figure 5. Tissue sections from static (left A) and dynamic (left B) environments
were individually placed between Instron grips (right) for compression testing.

Young’s modulus was calculated for 75-95% strain, 𝜀𝜀, with the key assumption that the

stress-strain relationship is linear and therefore, the EAs are acting as a purely elastic material for
0.75 < 𝜀𝜀 < 0.95. The following equation was used to calculate Young’s Modulus, E75-95%:
𝜎𝜎 = 𝐸𝐸75−95% ∗ 𝜀𝜀
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Equation 1

Histology
Aged EAs were placed in 10% formalin for 48 hours, dehydrated and sectioned for
hematoxylin and eosin (H&E) staining. All histology samples were processed by a trained
histologist in the Department of Poultry Science at the University of Arkansas. As composition
of static EAs has been reported, these values were compared to results from EAs formed in the
three aforementioned dynamic environments. Stained tissue sections were imaged with a Nikon
Eclipse Ci-L/S Microscope (Japan) and analyzed for fibrin/platelet to red blood cell ratios with a
custom MATLAB code, which will be discussed in the section 2.5.1 Composition Analysis. At
least three EAs of each dynamic environment were formed and processed to obtain a minimum
of three sections per clot. Three EAs were formed at 34 RPM, five at 50 RPM and four at 80
RPM. Tissue sections were imaged and analyzed to provide an overall composition percentage of
fibrin/platelets and RBCs for EAs formed at 34 RPM (n=14), 50 RPM (n=23) and 80 RPM
(n=12).
Static EA tissue sections were difficult to obtain completely intact as the center of the
section was frequently washed out. This pointed towards the tissue remaining unfixed in the
center. Therefore, static EAs were quartered for the fixation process and then brought to
histology, but exhibited similar issues. Thicker sections were cut; however, the tissue appeared
cracked and composition analysis could not be formed. Due to similarity in static EA formation
with the procedure established by Duffy et al. (2016), composition analysis of their static EAs
were used for comparison with histology results from the dynamic EAs discussed.
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Composition Analysis
From images of H&E stained tissue sections, normalization and color deconvolution
produced images specific to hematoxylin and eosin stained components. To minimize bias from
staining and imaging differences, a reference matrix provided stain vectors to normalize the
images for direct comparison (Veta, 2015). The method of image normalization is based on the
algorithm from Macenko et al. (2009) and code describing Macenko’s algorithm (Khan, 2015;
Veta, 2015). Normalization of the image begins with converting the original image (Figure 6)
into its optical density (OD) image (Figure 7) as follows:

𝑂𝑂𝑂𝑂 = − log �𝐼𝐼�𝐼𝐼 �
0

Equation 2

where the image intensity (I) is divided by the light intensity entering the slide (𝐼𝐼0 ), which

is 255.
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A

B

Figure 6. H&E stained sections of dynamic EAs. (A) EA formed at 80 RPM demonstrates a
lightly stained tissue as well as a fibrin-rich section and (B) EA formed at 34 RPM that
represents overstained tissue and mixed composition of fibrin and RBCs. Vertical and
horizontal axes indicate image dimensions in pixels.

A

B

Figure 7. Optical density (OD) images of tissue sections from (A) EA formed at 80 RPM and
(B) EA formed at 34 RPM. Axes indicate image dimensions in pixels.
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The OD matrix must be reshaped to have three columns that correspond to values in the
red, green and blue channels. The low OD values with a threshold of 0.15 are removed from the
matrix (Macenko et al., 2009). The right eigenvectors calculated from the OD matrix create a
plane based on the two largest eigenvalues where the OD pixels are then projected onto that
plane. The angle between each pixel and the first eigenvector are calculated to create scalar
values at each point. The 1st and 99th percentile of the angles provide the angle extremes which
can be converted back to OD space and provide stain vectors corresponding to hematoxylin and
eosin. These are the stain vectors that can replace the original reference matrix if a specific
reference image is desired.
Color deconvolution is based on a previously established method and additional work
describing this method (Ruifrok & Johnston, 2001; Veta, 2015). Once the stain vectors are
calculated, the OD matrix (M) is formed first with the largest stain vector, which corresponds to
hematoxylin, and second with the smaller stain vector, which corresponds to eosin. The two stain
concentrations (C) are calculated based on the following equation:

𝐶𝐶 = 𝑀𝑀−1 [𝑦𝑦]

Equation 3

where y corresponds to the OD image after reshaping, but prior to thresholding. The
concentrations may then be multiplied by the reference matrix and its exponential produces
images of the hematoxylin-stained components and the eosin-stained components (Figure 8).
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A

B

C

D

Figure 8. Color deconvolution results in (A) eosin stained image of EA formed at 80
RPM, (B) eosin stained image of EA formed at 34 RPM, (C) hematoxylin stained image
of EA formed at 80 RPM and (D) hematoxylin stained image of EA formed at 34 RPM.

Fibrin and RBCs are the main components of thrombi but are both stained pink-red with
eosin. The eosin-stained image provides a platform to extract the composition data based on
fibrin and RBCs. A threshold of 0.97 for the red channel of the eosin-stained image removes a
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majority of white space in the image and results in background masks as seen in Figure 9. This
ensures that the composition analysis is performed only on pixels represented by tissue that
absorbed eosin. The threshold was manually adjusted and qualitatively analyzed for the optimal
threshold that removes a majority of white space without removing the lightly-stained fibrin.

A

B

Figure 9. Background masks of EAs formed at (A) 80 RPM and (B) 34 RPM completely
remove pixels representing white or lightly colored background to ensure background pixels
are not included in the individual summations of fibrin and RBC pixels.
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A

B

C

D

Figure 10. Masks represented by white space or 1’s in the matrix are equivalent to (A) fibrin
in EA formed at 80 RPM, (B) fibrin in EA formed at 34 RPM, (C) RBCs in EA formed at 80
RPM and (D) RBCs in EA formed at 34 RPM.
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A

B

C

D

Figure 11. Masks overlaid on eosin stained images represent (A) fibrin in EA formed at 80
RPM (B) fibrin in EA formed at 34 RPM, (C) RBCs in EA formed at 80 RPM and (D) RBCs
in EA formed at 34 RPM.
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Then, a threshold separating the two average intensity values produces two masks to
correspond with either fibrin/platelets or RBCs. Given the masks are matrices of zeros and ones,
the ones may be summed together to compute the number of pixels that correspond respectively
to fibrin/platelets and RBCs. These masks may be seen in Figure 10. Dividing these by the total
number of pixels relative to the tissue in the image, a composition percentage for RBCs as well
as fibrin/platelets may be calculated. Through comparison of resulting mask images over the
eosin-stained tissue, a common threshold of 0.87 was identified in the red channel of the images
to separate out the fibrin/platelet pixels from the RBC pixels. Masks overlaid on the eosinstained images are shown in Figure 11.
This method was unable to properly calculate composition percentages for seven tissue
sections for unknown reasons. Five of the seven sections were clearly fibrin-rich tissue sections,
yet the method identified over 50% of the tissue section as RBCs. Therefore, calculations from
these tissue sections were discarded. After these were discarded, each EA still had at least three
tissue sections for comparison, which allowed for composition analysis for 87% of the H&E
stained tissue slides. The MATLAB code written for the composition analysis is documented in
Appendix A.

Flow System
Design Criteria
The key parameters to establish for this model include temperature and volumetric flow
rates. The temperature of the system must correspond to the body’s natural temperature of 37˚C
(98.6 ˚F). As previously mentioned, the MCA mean flow rate is 121 ± 28 ml/min and the ICA
mean flow rate is 240 ml/min, while the BA mean flow rate lies between 100-200 ml/min
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(Kandel et al., 2000; Oktar et al., 2006; Stock et al., 2000). Pressures and flow rates experienced
during a stroke will occur once an embolus is introduced into the in-vitro stroke model. This
system must incorporate the vessel model to allow for embolization with EAs and prototype
testing for stroke research.

Implementation
Instrumentation used to simulate, control and monitor the AIS parameters of the completed
system is shown in Figure 12. The temperature of the water bath was adjusted to correspond to
physiological temperature within the flow loop. Styrofoam peanuts were layered on the water
within the water bath to provide additional insulation and prevent heat loss. A high accuracy J/K
dual input thermocouple thermometer HH802U (Omega, Norwalk, CT) measured the
temperature of the water bath and inlet temperature of the vessel model. Masterflex® C-flex
Ultra L/S 17 Tubing (Cole-Parmer, Vernon Hills, IL) was used with a digital peristaltic pump
(Model 7523-50, Cole-Parmer, Vernon Hills, IL) to pump distilled water from a glass container
placed within the water bath to the flow loop system. Due to the pulsatile flow, a pulse dampener
(Cole-Parmer, Vernon Hills, IL) was necessary to ensure accurate flow rate readings from a SRI2 Indicator (Flow Technology Inc., Phoenix, AZ) connected to a turbine flow meter (FT0-3,
Flow Technology Inc., Phoenix, AZ).
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Figure 12. Instrumentation used to simulate, control and monitor the AIS parameters of the invitro system

After the pulse dampener, polyvinyl tubing was primarily used apart from silicone tubing
immediately prior to and after the silicone model. A t-shaped connector after the flow meter
linked additional tubing to form a bypass and eliminate pressure build-up once an EA would be
introduced to the system and stop fluid flow for prototype testing. Another t-shaped connector
provided a port for one of the thermocouples to measure inlet temperature of the silicone
vascular model (Figure 13). This was immediately followed by a y-shaped connector that acted
as point to introduce an EA as well as a retrieval mechanism to the model. Specifics of the
silicone vascular model will be discussed in the subsequent section 2.7 Silicone Mold of
Cerebral Arteries.
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Figure 13. Thermocouple measures temperature
at vascular model inlet within t-connector

Silicone Model of Cerebral Arteries
Design Criteria
Of 531 patients from 11 clinical studies, the location of occlusion occurred in the MCA
most frequently at 56.7% followed by the ICA at 33.7%, BA at 7.2%, posterior cerebral artery
(PCA) at 3.0% and anterior cerebral artery (ACA) at 0.4% (Boeckh-Behrens et al., 2016; Chueh
et al., 2011; Cline et al., 2013; Hashimoto et al., 2016; S. K. Kim et al., 2015; Krajíčková et al.,
2017; Liebeskind et al., 2011; Marder et al., 2006; Niesten et al., 2014; Schuhmann et al., 2016;
Simons, Mitchell, Dowling, Gonzales, & Yan, 2015). As the PCA and ACA incur a small
percentage of strokes, the MCA, ICA and BA were chosen to be replicated with a cerebral
vasculature void in a silicone mold. The design criteria based on the MCA, ICA and BA included
vessel diameter, length and tortuosity. The mean vessel diameter of the MCA is 2.8 mm (0.11
in), while the ICA mean diameter is 5.1 mm (0.20 in) and the BA mean diameter is 3.2 mm (0.12
in) (Oktar et al., 2006; Smoker, Price, Keyes, Corbett, & Gentry, 1986; Stock et al., 2000).
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Another design criterion was to ensure that the vasculature model could be easily replicated as
well as altered to produce alternative cerebral or cardiovascular models.

Implementation
Chemical and heat treatments are common to remove one material while leaving the
desired material behind. Both were explored regarding ballistics gel, silicone and available
materials for additive manufacturing such as ABS and polylactic acid (PLA). Ballistics gel was
found to have too low of a melting temperature in comparison to PLA and ABS whereas the
melting temperature difference between silicone, ABS and PLA offered a possibility of using a
heat treatment. Investigating solubility properties of ABS and PLA with silicone offered a safe,
simple alternative to a heat treatment.
Modeling of the desired vessels in SolidWorks resulted in a lumen 3D printed in ABS with
an Ultimaker (Ultimaker B.V., Geldermalsen, Netherlands). The lumen print was suspended in a
customized acrylic box and covered with platinum cure silicone (Raw Material Suppliers, San
Marcos, CA). Silicone was allowed to cure overnight at room temperature and then chemically
treated to remove the ABS lumen material. Due to proprietary information, the specifications of
the chemical treatment are not discussed. Two iterations of a silicone mold were completed due
to the first prototype incurring bubbles in the cured silicone hindering a clear view of the vessel
and design changes to the tortuosity as well as the connection between the flow loop tubing and
vessel model.
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Statistical Analysis
Outliers from compression testing were removed with Grubbs’ test in GraphPad
QuickCalcs (San Diego, CA). Subsequently, statistical significance between groups was found
with t test also in GraphPad QuickCalcs (San Diego, CA). Values are reported in terms of mean
+/- standard deviation unless otherwise specified.

Results
Emboli Analog Dimensions
Length and width of EAs formed in each environment were averaged for comparison with
human stroke thromboemboli retrieved in a clinical study by Marder et al. (2006). Dynamically
formed EAs had a length of 15.1 +/- 9.4 mm and width of 3.1 +/- 0.6 mm, which most closely
resembled stroke thromboemboli retrieved from the ICA with a length of 10.1 +/- 10.2 mm and
width of 2.8 +/-1.2 mm (Marder et al., 2006). Those from the MCA had a length of 3.1 +/- 1.5
mm and width of 1.8 +/- 0.8 mm (Marder et al., 2006). Static EAs with a length of 65.7 +/- 2.9
mm were twice the maximum length of emboli retrieved by Marder et al. (2006) in their study of
25 patients. Average width of the static EAs was 4.7 +/- 0.6 mm. Figure 14 demonstrates the
heterogeneity of the dynamic EAs versus the homogeneous static EAs. From the 1-3 mm mark of
Figure 14A, compacted RBCs may be seen within the fibrous structure. While the dynamic EAs
were flexible, they maintained their shape longitudinally and transversely. Once the static EAs
were removed from the tubing, they flattened slightly into an oblong shape in the transverse
direction.
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A

B
Figure 14. Images of (A) dynamically formed emboli analog and (B)
static emboli analog.

Emboli Analog Material Stiffness
Storage Conditions
Material stiffness of emboli analogs stored for 24 hours and 1 week in saline determined
the feasibility of storing clots long-term for continued use in prototype testing. Figure 15
demonstrates that a two-fold increase in material stiffness was found between EAs stored for 24
hours and 1 week. The average 𝐸𝐸75−95% values for 24 hour and 1 week storage were 1.57 +/0.35 MPa and 3.30 +/- 1.84, respectively and did not show statistical significance (p=0.07).
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Figure 15. Boxplot of Young’s modulus for strain range of
75-95% of emboli analogs formed at 50 RPM stored in
PBS for 24 hours and 1 week (p=0.07).

Dynamic vs. Static Environment
Previous studies on the mechanical properties of pure fibrin clots offer insight to
examining the compression testing data from the static and dynamic EAs. Typical compressive
stress-strain plots of pure fibrin clots contain three regions including a linear elastic portion for 𝜀𝜀

< 0.05-0.15, an elastoplastic plateau until 𝜀𝜀 = 0.3-0.5, and non-linear stiffening of the clot for 𝜀𝜀 >
0.5 (Kim, 2014). The third region mentioned is described as strain hardening, which is common
in biological gel-like structures (Weisel, 2017). Strain hardening is likely due to filaments
resisting buckling under compression and increased fiber densification (Kim, 2014). In Figure
16, an example of the stress-strain curve for a pure fibrin clot from Kim et al. (2014) is compared
with the resulting compression testing data for EAs formed at 50 RPM and 80 RPM, which
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represent a low (1.45 MPa) and high (3.63 MPa) Young’s modulus, respectively, for the two
tissue segments. Graphs resulting in a higher Young’s modulus are similar to the stress-strain
curves exhibited by pure fibrin clots indicating composition may contribute to the mechanical
strength of the EA.
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Figure 16. Normal stress, 𝜎𝜎, vs. strain, 𝜀𝜀, of (A) pure fibrin clots
(O. V. Kim, Litvinov, Weisel, & Alber, 2014), and (B) dynamic
EA formed at 50 RPM, and (C) dynamic EA formed at 80 RPM
d i thi t d
The assumption of a purely elastic material, and therefore linear stress-strain relationship at
75-95% strain, proved true for a majority of the data. Average R2 values were follows: 0.95 (0
RPM), 0.97 (34 RPM), 0.95 (50 RPM), and 0.97 (80 RPM). The lowest R2 value overall was
0.87 in the mechanical testing data. This assumption was based on experiments conducted by
Chueh et al. (2011) for the comparison of the proposed EAs to their findings on the material
stiffness of thrombi.
Results from compression testing shown in Figure 17 exhibit a general upward trend of
material stiffness with increasing flow rate. Young’s modulus for the various environments are
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compared with CEA thromboemboli in Table 1. Note that these values are reported as mean +/SEM. Statistical analysis found a significant difference (p<0.5) between the static EAs and each
of the dynamic EAs. In comparison with the CEA thromboemboli, the static EAs and dynamic
EAs at 102 mL/min and 150 mL/min were not statistically significant.
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Figure 17. Boxplot of Young’s modulus for strain range of 75-95% of static
and dynamic emboli analogs (EA).
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Table 1. Means and SEM of material stiffness comparison between
static and dynamic emboli analogs and thromboemboli extracted
from carotid endarterectomy (CEA). P-values for statistical
significance with CEA Thromboemboli are also reported. *Value
from Chueh et al. (2011)
𝑬𝑬𝟕𝟕𝟕𝟕−𝟗𝟗𝟗𝟗% (MPa)

p-values

Static EA (n=9)

1.17 +/- 0.12

0.457

EA @ 34 RPM (n=10)

2.70 +/- 0.15

0.058

EA @ 50 RPM (n=9)

1.58 +/- 0.13

0.972

EA @ 80 RPM (n=9)

3.36 +/- 0.30

0.011

CEA Thromboemboli* (n=11)

1.60 +/- 0.50

Emboli Analog Physiological Properties
Fibrin/platelets and RBCs of the dynamic EAs were analyzed through histology and image
analysis as they are the primary components of thromboemboli. Images of the EAs are compared
with previously published images of RBC-rich and fibrin-rich thrombi in Figure 18. Figure 18A
shows a section of a RBC-rich thrombus whereas the section in Figure 18B is fibrin-rich.
Although static EA tissue sections were difficult to obtain, several showed similarities in
exhibiting loose connective fibrin on the perimeter of the EA and predominantly cherry-red or
magenta stained RBCs in the middle as shown in Figure 18C. Figure 18D and Figure 18E are
examples of tissue sections from EAs formed at 34 RPM and 50 RPM, respectively. Both
samples show layers of light pink fibrin interspersed with individual RBCs as well as large and
small clusters of RBCs. Figure 18F shows a fibrin-rich tissue section of an EA formed at 80
RPM. A few clusters of RBCs are scattered throughout the tissue sample as well as individual
cells. Blue WBCs may be seen in all tissue samples.
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As platelets cannot be distinguished from fibrin with H&E staining, they were reported
together relative to RBCs in Figure 19. Further breakdown of compositions for each tissue
section analyzed is summarized in Appendix B. Percent area of fibrin in the tissue sections for
each dynamic environment are as follows: 63.29+/-13.00% (34 RPM), 67.84 +/- 21.40% (50
RPM) and 78.03 +/- 20.43% (80 RPM). Additionally, the percent areas of RBCs were: 36.71 +/13.00% (34 RPM), 32.16 +/-21.40% (50 RPM) and 21.97 +/- 20.43% (80 RPM). In comparison,
Duffy et al. (2016) reported that the percent area of fibrin for their static EAs was 7.82 +/2.75%. Percent area of RBCs was 91.21 +/- 2.98% for their static EAs formed from sheep blood
(Duffy et al., 2016).
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C

D

E

F

Figure 18. H&E staining of emboli analogs (EAs) created in four environments. A)
RBC-rich thrombus (Liebeskind et al., 2011) B) Fibrin-rich thrombus (Liebeskind et
al., 2011) C) Loose connective fibrin (arrows) located where RBC-rich clot formed
against the tubing in a static environment (20X magnification). D) Vertical rotator
speed equivalent to 34 RPM. EA is interspersed with RBCs in fibrin, platelets and
leukocytes (10X magnification). E) EA formed at 50 RPM containing RBCs, fibrin,
platelets and leukocytes (10X magnification). F) Vertical rotator speed was 80
RPM. EA contains some RBCs with primarily fibrin and platelets interspersed with
leukocytes (10X magnification).
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Figure 19. Trend of increasing amounts of fibrin/platelets and decreasing ratio of
RBCs within the emboli analogs as a function of increasing volumetric flow rate.
Note that data at 0 RPM is from Duffy et al. (2016).

In-Vitro AIS Simulation Model
Temperature Regulation
The desired physiological temperature of 37˚C (98.6 ˚F) was maintained during all
experiments by adjustment of the water bath temperature. The temperature was set slightly
higher (44˚C) than 37˚C to ensure that the inlet temperature of the vascular model would
correspond to the body’s natural temperature. The thermocouple thermometer measured and
compared the water bath temperature and inlet temperature. Large fluctuations of the
temperature were reduced after approximately one hour when steady-state conditions were
reached and the temperature continued to slightly fluctuate within less than 2˚C.
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Flow Rate Analysis
The desired flow range of 100-240 ml/min was achieved through pumping distilled water
from a reservoir in the water bath to the system. The RPM on the peristaltic pump was altered to
induce the flow rate and the corresponding output of the flow rate indicator was recorded. The
flow rate was measured with a stopwatch and plastic beaker on a digital scale. Trials were
repeated for a range of pump speed from 30 to 100 RPM. The RPM, volumetric flow rate and
indicator value were recorded in a spreadsheet to create the following equations:
𝑄𝑄 = 2.52 ∗ 𝑅𝑅𝑅𝑅𝑅𝑅 + 2.78

Equation 4

𝑄𝑄 = 1113.5 ∗ 𝐼𝐼𝐼𝐼 + 24.264

Equation 5

where Q is the volumetric flow rate (ml/min), RPM is the pump speed and IV is the
indicator value from the digital flow rate indicator. These equations allow for the calculation of
the system flow rate based on the pump speed as well as the output from the flow rate indicator.
Both data sets fit the computed linear trendline well as the R2 values were 0.99 and 0.99 for
Equation 4 and Equation 5, respectively.

Replication of Cerebral Arteries
The first AIS vascular prototype was created with a confidential process. A primary
complication from the initial prototype included bubbles forming in the silicone and hindering a
clear view of the vessel conduit within the cured silicone model (Figure 20). After testing the
model with an aspiration catheter Aspire RX-LP6 (Control Medical Technology, Hallandale, FL)
one vessel angle was deemed too sharp to navigate the catheter through the conduit. A second
iteration of the vascular model was prepared to reformat the connection between the model’s
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outlets and tubing, minimize bubbles within the silicone, alter the vessel angles, and include a
bifurcation within the model.

Figure 20. First prototype of silicone vessel model

In the second iteration, the vessel was altered to have the ICA bifurcate into the MCA and
BA. Although physiologically the BA does not attach to the ICA, this simplified the model to
test a prototype in three vessels where stroke most commonly occurs. Note that this bifurcation
does not follow Murray’s Law for parent and daughter diameters in the following equation:
𝑟𝑟0 3 = 𝑟𝑟1 3 + 𝑟𝑟2 3

Equation 6

where 𝑟𝑟0 is the radius of the ICA while 𝑟𝑟1 and 𝑟𝑟2 are the radii for the MCA and BA.

Therefore, uniform shear stress within the network may not be assumed (Hoganson et al., 2010).
The vessel diameters were simplified to be 5 mm, 2.5 mm and 3 mm for the ICA, MCA
and BA, respectively. This allowed for a direct connection of the vessel conduit to silicone
tubing (Uxcell, Hong Kong) and eliminated the connection issue previously described in the first
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iteration. These diameters were found to be within the physiological range for each vessel (Oktar
et al., 2006; Smoker et al., 1986; Stock et al., 2000). Based on literature, the length of the ICA,
MCA and BA were chosen to be 8.5 cm, 20 mm and 30 mm, respectively (Choudhry, Grantham,
Rai, & Hogg, 2016; Pai, Varma, & Kulkarni, 2005; Zhang et al., 2014). Bubbles in the silicone
were eliminated by degassing the silicone in a vacuum pressure chamber immediately after
mixing but prior to pouring. Several bubbles formed on the sides of the acrylic box and top
surface exposed to the air during the curing process; however, the bottom of the mold was
completely clear as seen in Figure 21. The sharpest vessel angle was changed to 74.4º, which is
the mean angle of cerebral vasculature (Canham & Finlay, 2004).

MCA

ICA
BA

Figure 21. Second prototype of silicone vessel model
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Discussion
Emboli Analog Dimensions
Blood volume and tubing width were optimized with the dynamic system to produce EAs
with similar dimensions of stroke thromboemboli retrieved from the ICA. Although statically
formed EAs were longer, the blood volume could be adjusted to obtain statically formed EAs
with dimensions resembling stroke emboli as well. Blood volume and tubing width could also be
altered to obtain EAs mimicking dimensions of thromboemboli from other vessels. For direct
comparison of material stiffness and composition between the static and dynamic environments,
all parameters excluding the induced volumetric flow rate remained the same. With the proposed
method, EAs can be easily formed in a dynamic system to resemble dimensions of stroke emboli
extracted from the ICA.

Emboli Analog Material Stiffness
Storage Conditions
As storage conditions were not statistically significant (p=0.07), EAs stored in PBS for one
week could be used for prototype testing. However, the material stiffness of the EAs stored for
one week exhibited large variations reflected in the high standard deviation. The average
𝐸𝐸75−95% for one EA was 6.41 MPa, which is four times the average 𝐸𝐸75−95% of retrieved

thromboemboli from CEA procedures (Chueh et al., 2011). Unpredictability of the EA material
stiffness during prototype testing may skew results, and therefore EAs are not recommended to
be stored in PBS for one week.
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Emboli Analogs vs. Human Stroke Thromboemboli
Approximately 11% of the tissue segments analyzed exhibited non-linear deformation after
an initial yield point. In addition to the date shown in Figure 22, stress-strain curves with the
same non-linearity are also shown in Appendix C. Over 60% of those tissue segments were from
statically formed EAs, suggesting that the composition of the EAs contributed to the nonlinearity.
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Figure 22. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, of A) static EA and B) dynamic EA
(50 RPM) demonstrate non-linearity after initial yield point followed by continued strain
hardening of the fibrin in each EA. Young’s modulus is calculated for data points from 75%
strain until 95% strain or initial yield point is reached.

In Figure 22, the initial yield point may be due to failing of the mechanical strength of
RBCs, whereas the fibrin-platelet network continues strain hardening until permanent
deformation occurs. Individual fibrin fibers have been found to unfold from their typical coiledcoil structure to become 𝛽𝛽-sheets under compression (Weisel, 2017; Kim, 2014). One analogy to

describe the stress-strain relationship exhibited may be water balloons (RBCs) intertwined with a
spring (fibrin). Once the balloon or cell membranes break, the spring will continue to deform
under the applied load until it experiences permanent deformation. As this phenomenon was
43

found most frequently in static EAs, it is most likely composition dependent. The dynamic EAs
that exhibited similar behavior may be due to a higher percentage of RBCs within the specific
sample tested. In Figure 14A of the example dynamic EA, a small red portion may be inferred as
RBC-rich whereas the rest of the sample within view is predominantly fibrin.
Stress-strain curves of the dynamic EAs revealed a brief decrease in strain for a short strain
range versus stress-strain curves of static EAs that decreased and then began strain hardening for
a longer strain range. This also points towards the described phenomenon being composition
dependent as the static EAs had a higher percentage of RBCs than the dynamic EAs.
The dynamic method discussed demonstrates the ability to offer EAs with a range of
compositions and mechanical properties for prototype testing. Table 1 reveals that porcine
emboli formed at 50 RPM exhibit mechanical properties nearly identical to thromboemboli
extracted from CEA (p=0.972). These thromboemboli were described as highly inhomogeneous;
however, exact compositions were not documented (Chueh et al., 2011). Fibrin-rich clots have
been identified as a cause for recanalization issues (Hashimoto et al., 2016; Yuki et al., 2012).
Therefore, the dynamic process at 50 RPM should be used to produce EAs that are fibrin-rich
and mimic the material stiffness of human stroke thromboemboli.

Emboli Analog Physiological Properties
Emboli Analogs vs. Human Stroke Thromboemboli
Chueh et al. (2011) discussed the need to create an emboli analog model to test and modify
endovascular recanalization devices as the mechanical properties of the model will determine the
device performance. The emboli analogs developed from human, porcine and bovine blood were
composed of primarily RBCs surrounded by a thin outer layer of fibrin where the emboli analog
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had developed against the tubing. Similarly, our static EAs also exhibited a thin band of fibrin
circulating the RBCs where the EA had been in contact with the tubing. Arrows in Figure 18C
point to loose connective fibrin at the edge of the tissue section. Although Chueh et al. (2011)
created emboli analogs similar in material stiffness to the human stroke thromboemboli, the
histological findings concur that simply adding various concentrations of thrombin, blood and
coagulant will result in a homogeneous EA. Nearly 70% of thromboemboli retrieved in three
clinical studies were described as having a serpentine or layered pattern of fibrin, RBCs, platelets
and WBCs (Cline et al., 2013; Marder et al., 2006; Schuhmann et al., 2016). Similar patterns are
achieved in the dynamically formed EAs as seen in Figure 18.

Material Stiffness vs. Composition Results
While the histology results appear to be conclusive that increasing flow rates result in
increasing amounts of fibrin/platelets and an inverse relationship with RBCs, the results do not
correspond with the discrepancy between the material stiffness results. For example, at 34 RPM
the material stiffness was higher than at 50 RPM. One explanation may be the fibrin morphology
differences as one study found that maximum clot stiffness correlated with thick fibers and
highly branched fibrin (Ryan, Mockros, Weisel, & Lorand, 1999). The authors note that fiber
thickness and branching are inversely related; therefore, these two parameters must be in
“equilibrium” to exhibit maximum clot stiffness. This may be plausible for EAs formed at 34
RPM as the RBCs generally were found in clusters, which would allow thicker fibers to form
around the RBC clusters. Additionally, RBCs scattered within the fibrin may encourage
branching of the fibrin network. Distribution of RBCs may point to how fibrin fibers form within
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the EAs, which may be examined through images from a scanning electron microscope (SEM) to
indicate fiber alignment, diameter as well as RBC distribution.
Distribution of RBCs within the fibrin network may also contribute to differences in
material stiffness. One study found that platelet and fibrin concentrations influence RBCs
contracting to a polyhedral formation, aptly named polyhedrocytes (Cines et al., 2014). As the
polyhedral structure results in an efficient, tight-packing of RBCs, material stiffness of these
clots would be higher than EAs with RBCs evenly distributed within the fibrin network.
Additionally, Cines et al. (2014) observed erythrocytes excluded during clot formation, which
they hypothesized was due to platelet contraction initiating clusters of polyhedrocytes and
simultaneously forcing some erythrocytes from the fibrin network. This concurs with our
findings that at higher blood flow rates, and therefore higher external forces, more platelets and
fibrin formed while the percentage of RBCs was low. SEM may provide a deeper insight to the
differences in the material stiffness of EAs formed at 34 RPM and 50 RPM.

In-Vitro AIS Simulation Model
Temperature regulation of the in-vitro AIS simulation model was successfully achieved to
obtain the physiological temperature of 37 ºC. The pump speed, flow rate indicator value and
volumetric flow rate were correlated to produce two equations. This allows the user to input a
specific pump speed for the desired flow rate and compare with the output from the flow rate
indicator. From a separate trial, the error between the two equations was calculated to be 0.16%
from a pump speed of 70 RPM and indicator value of 0.139. To obtain an inlet flow rate of 240
mL/min corresponding to the ICA, a pump speed of 94 RPM is recommended. This setting
should produce an indicator value of 0.193 for the desired flow rate.
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Two iterations of the silicone vascular model provided a final model with dimensions
similar to the ICA, MCA and BA in terms of their diameter, length and tortuosity. As ABS is a
common material in additive manufacturing, the majority of 3D printing equipment should be
able to replicate any desired vasculature for research purposes. Clear visibility of the vessel
allows for a camera to capture embolization and removal during prototype testing. This mold
provides a platform that may be easily altered to explore alternative cerebral vasculature for
stroke research.

Limitations
Image size of the tissue sections remains one limitation for the composition analysis used
for this research. Future adjustments for the MATLAB code could include breaking the images
into smaller segments to increase the number of pixels for each total image examined by the
MATLAB code and therefore, increase threshold sensitivity. Other limitations include a small
sample size (n) for the composition analysis and material stiffness data. One method of storage
was explored, yet other methods may provide appropriate conditions for storage of EAs longterm. Also, the volumetric blood flow rate is relative to low, medium and high speeds rather than
exact flow rates. This is due to a small portion of the blood thinning out along the tubing wall.

Future Directions
Further analysis of EA material stiffness and composition analysis include additional
staining methods and SEM. Platelets and fibrin were calculated together, yet platelets could be
separated using immunohistochemistry staining methods to identify exact compositions of
platelets, fibrin and RBCs. Alternative staining methods to examine fibrin/platelets and RBCs
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include Martius, Scarlet and Blue (MSB). Previous research has found no significant difference
between H&E and MSB staining methods for identifying the content percentage of RBCs,
fibrin/platelets and WBCs (Duffy et al., 2016). Another component to examine may be
atheromateous gruel, which is cholesterol clefts or foam cells. Of 251 patients examined for
atheromatous gruel, 11 (4.4%) thromboemboli were positive (Chueh et al., 2011; Hashimoto et
al., 2016; S. K. Kim et al., 2015; Krajíčková et al., 2017; Marder et al., 2006; Niesten et al.,
2014). WBCs may be another component of the EAs to examine as cardioembolic thrombi have
more WBCs than noncardioembolic thrombi (Sporns et al., 2017). Material stiffness of EAs
could be further examined with SEM to indicate the microstructure and investigate fibrin fiber
alignment, fiber diameter and RBC distribution. Thus, clot etiology may be further explored
through identifying multiple components of EAs and comparing with human stroke
thromboemboli.
Using advances in imaging modalities, researchers are linking clot composition with
imaging artifacts (Liebeskind et al., 2011; Simons et al., 2015). Liebeskind et al. (2011)
examined the link between CT and MRI imaging markers with pathology of thrombi obtained
from human stroke patients. Specific imaging features included hyperdense middle cerebral
artery sign on CT and gradient-echo blooming artifact on MRI. Simons et al. (2014) also
examined the CT imaging feature hyperdense artery sign (HAS) for comparison with thrombus
composition. They used CD34 to identify endothelial cells in thrombi. If positively identified, the
endothelial cells demonstrated that the sample was a late phase organized fibrin thrombus. HAS
was found more frequently in early phase thrombi (65.5%) versus late phase thrombi (34.5%)
(Simons et al., 2015). From this knowledge, one may be able to know the type of stroke clot and
adapt the retrieval mechanism to the clot composition. With the proposed methodology of fibrin-
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rich EA formation, continued research on retrieval mechanisms specific to fibrin-rich
thromboemboli may be explored.
Regarding the in-vitro model to simulate AIS, temperature and flow rate data collection
could be automated with LABVIEW. This would allow for a feedback control loop to ensure that
the temperature and flow rate remain constant during prototype testing of a retrieval mechanism.
Distilled water in the flow loop may be replaced by a 40% (w/v) glycerin solution to obtain a
fluid viscosity similar to blood. Additionally, ballistics gel is an alternative material to silicone in
the vascular model as it is known to effectively mimic human tissue properties.

Conclusions
Conditions used to create EAs have a significant impact on their composition and
mechanical properties. Static conditions will yield a comparable material stiffness to cerebral
thromboemboli, yet will be primarily composed of RBCs with a thin network of fibrin
surrounding the EA. Dynamic conditions may be altered to obtain EAs mimicking material
stiffness of CEA thromboemboli and compositions of varying percentages of fibrin, platelets and
RBCs. Specifically, the EAs formed at 50 RPM were found to be nearly identical in their
material stiffness with CEA thromboemboli (p=0.972). Long-term storage of EAs in PBS for one
week is not recommended due to the high variability in material stiffness of EAs stored for 1
week at 4°C. Testing of stroke retrieval mechanisms should be conducted with EAs that have
well-defined and validated characteristics that make them appropriate to represent human stroke
thromboemboli.
Through this project, a new method to replicate brain vasculature tortuosity and inner
diameters of the arteries has been developed. This system will ensure that the retrieval device
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could move realistically in human brain vasculature to extract a stroke clot. The described invitro model is essential to simulate AIS parameters and test prototypes of a mechanism for clot
retrieval in stroke patients.
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Appendix A: Automated Histology Analysis
%Goal: Automate the analysis of H&E stained sections of emboli analogs to
%determine the percentage of fibrin to red blood cells (RBCs) in the sample.
%(1) Perform normalization and color deconvolution of the histology images
%(2) Obtain Eosin stained image and compare percentage of fibrin to erythrocytes (RBCs)
%% References-------------------------------------------------------------------------------------------------%Khan, A.M. (2015, May 28). Stain Normalization Toolbox.
%Retrieved from: https://warwick.ac.uk/fac/sci/dcs/research/tia/software/sntoolbox/
%Macenko M, et al. "A method for normalizing histology slides for
%quantitative analysis", IEEE International Symposium on Biomedical Imaging:
%From Nano to Macro, pp. 1107-1110, 2009.
%Pathology Education Informational Resource Digital Library. (2013).
%Retrieved from: http://peir.path.uab.edu/library/index.php?/category/2
%Ruifrok AC, Johnston DA. Quantification of histological staining by color
%deconvolution. Anal Quant Cytol Histol 23: 291-299, 2001.
%Veta, M. (2015, Jun 8). Staining-normalization. Retrieved from:
%https://github.com/mitkovetta/staining-normalization/blob/master/normalizeStaining.m
%% Normalize Histology Slides ----------------------------------------------------------------------------%Note: Method based on (Macenko, 2009) & (Khan, 2013)
clear all
%Reference OD matrix for H&E staining
Mref = [
0.5626 0.2159
0.7201 0.8012
0.4062 0.5581
];% directly from (Veta,2013)

% Load Image, Convert to Double & Normalize
img=double(imread('insert image name here'))/255; %normalize to [0,1]; 255 is Io, the intensity
% of light entering the specimen
%% --------------------------------------------------------------------------------------------------------------%Optical Density (OD)
OD=-log(img);
%figure; imagesc(OD); title ('OD Image', 'FontSize', 28); axis image;
%Reshape Matrix & Apply Threshold to RGB Channels
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ODR=reshape(OD,[],3);
beta=0.15;
ODmask = ODR(~any(ODR < beta, 2), :); %examine nonzero elements of array; from
%(Khan,2013)
ODmask = ODmask(~any(isinf(ODmask), 2), :);
%Calculate Eigenvectors to Create Plane
[V, D] = eig(cov(ODmask)); %code from (Khan,2013)
Plane = V(:,2:3); %eigenvectors(V) corresponding to two largest eigenvalues(D)
%Project OD Pixels onto Plane
Project=ODmask*Plane;
%Obtain Angle Between Point and First SVD Direction
angle = atan2(Project(:,2), Project(:,1)); %Note: this becomes a scalar; code from (Khan, 2013)
%Identify Angle Extremes
minang=prctile(angle,1); %From Khan,2013
maxang=prctile(angle,99);
%Convert to OD Space & Compute Stain Vectors for Hematoxylin & Eosin
V1 = Plane*[cos(minang); sin(minang)]; %Code adapted from Khan, 2013
V2 = Plane*[cos(maxang); sin(maxang)]; %Code adapted from Khan, 2013
%% Color Deconvolution to Hematoxylin & Eosing Specific Images --------------------------------%Note: Method based on (Ruifrok, 2001) & code from (Veta, 2013)
%Determine if V1 is Hematoxylin or Eosin
if V1(1) > V2(1) %code from (Veta, 2013)
M(1,:)=V1; %V1 = Hematoxylin
M(2,:)=V2; %V2 = Eosin
else
M(1,:)=V2; %V2 = Hematoxylin
M(2,:)=V1; %V1 = Eosin
end
%Transpose OD Matrix & y Values
M=M';
y=ODR';
%Calculate Stain Amount at Each Pixel
C=M\y; %from (Veta, 2013)
%Determine Image Size
size=size(img);
row=size(1);
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col=size(2);
% Produce Separate Hematoxylin & Eosin Images
H = exp(-Mref(:,1) * C(1,:)); %from (Veta, 2013)
HR = reshape(H', row, col, 3);
%figure; imagesc(HR); axis image; title ('Hematoxylin', 'FontSize', 28);
E = exp(-Mref(:,2) * C(2,:)); %from (Veta, 2013)
E = reshape(E', row, col, 3);
%figure; imagesc(E); axis image; title ('Eosin', 'FontSize', 28);
%% Calculate Fibrin vs RBC Estimate in Eosin Image -------------------------------------------------%Convert Eosin Image to Grayscale
Egray= mean(E,3);
%figure; imagesc(Egray); colormap gray; axis image; title 'Gray Image of Eosin';
%Mask Image for White Spaces
thresh = 0.97; %qualitatively optimized by comparison of three atrial thrombi images
mask= E(:,:,1) < thresh;
%figure; imagesc(mask); axis image; colormap gray;
%Create Masks
thresh=0.87; Egray = E(:,:,1);
EmaskF=(Egray>thresh); %mask of fibrin components
EmaskRBC=(Egray<thresh); %mask of RBC components
EmaskF=EmaskF.*mask; %apply mask of white values to fibrin mask
EmaskRBC=EmaskRBC.*mask; %apply mask of white values to RBC mask
figure;
subplot (1,2,1); imagesc(EmaskF.*E); colormap gray; axis image; title ('Fibrin Mask', 'FontSize',
28);
subplot (1,2,2); imagesc(EmaskRBC.*E); colormap gray; axis image; title ('RBC Mask',
'FontSize', 28);
%Calculate Percent Fibrin and RBCs in Eosin Image
numpixF=sum(sum(EmaskF)); %number of fibrin pixels from mask
numpixRBC=sum(sum(EmaskRBC)); %number of RBC pixels from mask
prcF=numpixF/(numpixF+numpixRBC); %percent fibrin
prcRBC=numpixRBC/(numpixF+numpixRBC); % percent RBC
%Display Percentage Values
P=[prcF, prcRBC];
disp(' prcF prcRBC'); %space required to align words over matrix P
disp(P);
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%Validation of Appropriate Masks & Intensities
%Note: Fibrin stains lighter than RBCs; therefore, fibrin intensity should be greater
F= EmaskF.*Egray;
RBC=EmaskRBC.*Egray;
%figure; imagesc(RBC); colormap gray; axis image; title ('RBC', 'FontSize', 28);
%figure; imagesc(F); colormap gray; axis image; title ('Fibrin', 'FontSize', 28);
avgF=sum(sum(F))/sum(sum(EmaskF)); %avg intensity of fibrin
avgRBC= sum(sum(RBC))/sum(sum(EmaskRBC)); %avg intensity of RBC
if avgF < avgRBC
error('Average intensity of fibrin is less than that of RBCs - double check code');
end
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Appendix B: Composition Results for Individual Tissue Segments
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Figure B 1. Composition percentages for tissue samples from EAs
formed at 34 RPM
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Figure B 2. Composition percentages for tissue samples from EAs formed at 50 RPM
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Figure B 3. Composition percentages for tissue samples from EAs
formed at 80 RPM
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Appendix C: Additional Figures of Non-linear Stress-Strain Graphs
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Figure C 1. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for static
EA tissue segment 195c.
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Figure C 2. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for static
EA tissue segment 196cb.

62

1

Normal Stress, 𝜎𝜎, MPa

0.2

0.15

y = 0.9282x - 0.6751
R² = 0.9532

0.1

0.05

0
0.75

0.8

0.85
0.9
Compressive Strain, 𝜀𝜀

0.95

1

Figure C 3. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for static
EA tissue segment 197c.

Normal Stress, 𝜎𝜎, MPa

0.25
0.2

0.15

y = 1.1613x - 0.8478
R² = 0.954

0.1

0.05

0
0.75

0.8

0.85
0.9
Compressive Strain, 𝜀𝜀

Figure C 4. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for static
EA tissue segment 198b.

63

0.95

Normal Stress, 𝜎𝜎, MPa

0.15
y = 0.735x - 0.5366
R² = 0.9756

0.1

0.05

0
0.75

0.8

0.85
0.9
Compressive Strain, 𝜀𝜀

0.95

Figure C 5. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for static
EA tissue segment 198c.
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Figure C 6. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for static
EA tissue segment 197b.
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Figure C 7. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for dynamic
EA (50 RPM) tissue segment 142a.
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Figure C 8. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for dynamic
EA (80 RPM) tissue segment 18b.
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Figure C 9. Normal stress, 𝜎𝜎, versus compressive strain, 𝜀𝜀, for dynamic
EA (34 RPM) tissue segment 162a.
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